BC Week In Review | Jun 30, 2014
Clinical News

Viibryd vilazodone: Phase III data

Top-line data from the double-blind, U.S. Phase III MD-07 trial in 415 adults with GAD showed that flexible doses of 20-40 mg/day oral Viibryd met the primary endpoint of improving HAM-A total score from baseline...
BC Week In Review | Jun 30, 2014
Clinical News

Viibryd vilazodone: Phase III data

Top-line data from the double-blind, U.S. Phase III MD-06 trial in 402 adults with GAD showed that flexible doses of 20-40 mg/day oral Viibryd met the primary endpoint of improving HAM-A total score from baseline...
BC Week In Review | Jun 30, 2014
Clinical News

Viibryd vilazodone: Phase III data

Top-line data from the double-blind, U.S. Phase III MD-05 trial in 680 adults with GAD showed that a 40 mg/day fixed dose of oral Viibryd met the primary endpoint of improving HAM-A total score from...
BioCentury | Jun 30, 2014
Finance

Highlights of weekly biotech stock moves

Regulatory milestones Basilea Pharmaceutica AG (SIX:BSLN) fell CHF9.10 to CHF104.90 last week after it said FDA confirmed additional Phase III data would be required to support U.S. approval of ceftobiprole to treat pneumonia. The company...
BC Extra | Jun 24, 2014
Clinical News

Forest planning Viibryd sNDA for GAD

Forest Laboratories Inc. (NYSE:FRX) reported data from three Phase III trials of Viibryd vilazodone to treat generalized anxiety disorder (GAD) and said it plans to submit an sNDA to FDA next year. In the MD-06...
BC Week In Review | Jun 23, 2014
Company News

moksha8 Pharmaceuticals Inc, Biopas deal

moksha8 partnered with Biopas to jointly commercialize specialty pharmaceuticals in Latin America. moksha8 has operations in Brazil and Mexico, while Biopas has operations in other Latin American countries, including Colombia, Venezuela, Argentina and Central America....
BC Extra | Jun 17, 2014
Company News

moksha8, Biopas to commercialize products in Latin America

moksha8 Pharmaceuticals Inc. (Wayne, Pa.) partnered with Biopas Group (Panama City, Panama) to jointly commercialize specialty pharmaceuticals in Latin America. moksha8 has operations in Brazil and Mexico, while Biopas has operations in other Latin American...
BC Week In Review | Jan 13, 2014
Clinical News

Viibryd vilazodone regulatory update

Marketing partner moksha8 Pharmaceuticals Inc. (Wayne, Pa.) said it submitted a regulatory application to Brazil's Agencia Nacional de Vigilancia Sanitaria (ANVISA) for Viibryd vilazodone to treat major depressive disorder (MDD). Forest markets Viibryd in the...
BC Week In Review | Jan 13, 2014
Company News

moksha8, Forest Laboratories deal

Forest no longer has an option to acquire moksha8 for $157 million. Forest gained the option under a 2012 deal in which the company granted moksha8 exclusive commercialization rights in Latin America to Forest's antidepressant...
BC Extra | Jan 7, 2014
Company News

Forest no longer has moksha8 option

Forest Laboratories Inc. (NYSE:FRX) no longer has an option to acquire moksha8 Pharmaceuticals Inc. (Wayne, Pa.) for $157 million. Forest gained the option under a 2012 deal in which the company granted moksha8 exclusive commercialization...
Items per page:
1 - 10 of 85